Dendreon Announces Management Promotions.Business Editors, Health/Medical Writers SEATTLE--(BW HealthWire)--Jan. 10, 2001 Dendreon Corporation (Nasdaq:DNDN) announced today key promotions among members of its executive management team. David L. Urdal, Ph.D., Dendreon's Chief Scientific Officer, has been promoted to President. Urdal joined Dendreon in 1995 from Immunex Corporation, where he served in various executive positions including President of Immunex Manufacturing Corporation. Martin A. Simonetti, Dendreon's Chief Financial Officer and Treasurer, has been promoted to Senior Vice President, Finance. Simonetti, who joined Dendreon in 1999, previously worked at Amgen Inc. as Vice-President Operations and Finance of Amgen BioPharma. Christopher S. Henney, Ph.D., D.Sc., Dendreon's Chief Executive Officer, has been appointed to the additional position of Chairman of the Board of Directors. As Chair of the Board, Henney replaces William Crouse, who held the position since 1995. Crouse, managing director of HealthCare Ventures LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , will remain a member of Dendreon's Board of Directors. Dendreon Corporation (www.dendreon.com) is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Dendreon is focused on the development of therapeutic cancer vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine through the use of antigen discovery, antigen engineering and dendritic cell dendritic cell n. 1. A cell that has branching processes. 2. Any of the cells in the neural crest of the embryonic ectoderm having extensive processes and developing early as producers of melanin. technologies. Dendreon's vaccine for the treatment of prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. , Provenge(TM), is in Phase III clinical trials, and its vaccine for the treatment of multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility , Mylovenge(TM), is in Phase II clinical trials. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion